Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1340-1345

  Ashby, J ^a   Garvey, L ^a,b   Erlwein, O W ^b   Lamba, H ^a   Weston, R ^a   Legg, K ^b   Latch, N ^b   McClure, M O ^b   Dickinson, L ^c,d   D'Avolio, A ^e   Back, D ^d   Winston, A ^a,b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

Antivirals; HCV; HIV; PK

Indexed keywords

RALTEGRAVIR; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SAFETY; ETHNICITY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RIBAVIRIN; YOUNG ADULT;

EID: 79956045755     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr093     Document Type: Article

References (27)

1. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-89.
2. Gazzard BG, Anderson J, Babiker A et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
3. Nunez M, Ocampo A, Aguirrebengoa K et al. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008; 15: 363-9.
4. Mira JA, Lopez-Cortes LF, Merino D et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 2007; 12: 1225-35.
5. Vispo E, Barreiro P, Maida I. Abacavir-containing HAART reduces the chances for SVR to peg-interferon plus RBV in HIV-infected patients with chronic hepatitis C. In: Abstracts of the Third International Workshop on HIV and Hepatitis Coinfection, Paris, France, 2007. Abstract 46.
6. Burger DM. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol 2010; 6: 1151-60.
7. Wenning LA, Hanley WD, Brainard DM et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2852-6.
8. Iwamoto M, Wenning LA, Nguyen BY et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48: 489-92.
9. Lertora JJ, Rege AB, Lacour JT et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991; 50: 442-9.
10. Lindahl K, Stahle L, Bruchfeld A et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-9.
11. Rodriguez-Torres M, Torriani FJ, Soriano V et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49: 3997-4008.
12. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65.
13. D'Avolio A, Ibanez A, Sciandra M et al. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 835: 127-30.
14. Moss D, Kwan WS, Liptrott N et al. Raltegravir is a substrate for the influx transporters OAT1 and PEPT1 and the efflux transporter Pgp but is not transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 2010. Poster 613. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
15. Andrews E, Glue P, Fang J et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010; 69: 51-7.
16. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2010; 85: 176-89.
17. Loustaud-Ratti V, Alain S, Rousseau A et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47: 1453-61.
18. Ribavirin Product Information, 2009. http://www.rocheusa.com/products/copegus/pi.pdf.
19. Chan AH, Partovi N, Ensom MH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C-a critical review. Ann Pharmacother 2009; 43: 2044-63.
20. Nicot F, Legrand-Abravanel F, Lafont T et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 2008; 80: 1523-9.
21. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.
22. Lau JY, Tam RC, Liang TJ et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9.
23. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005; 107: 165-71.
24. Zhang Y, Jamaluddin M, Wang S et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003; 77: 5933-47.
25. Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-8.
26. Moreno A, Quereda C, Fortun J et al. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage. AIDS 2010; 24: 1231-3.
27. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008; 30: 1747-65.